Fresenius (FRE) Q4 2024 earnings summary

Executive summary

• Achieved strong FY 2024 results with high single-digit organic revenue growth and double-digit EBIT and EPS growth, driven by Kabi and Helios performance.

• Successfully executed strategic portfolio measures, including deconsolidation of Fresenius Medical Care and exit from Vamed, streamlining the portfolio and increasing transparency.

• Structural improvements and productivity initiatives led to over €470 million in cost base savings and enhanced transparency and accountability.

• Dividend proposal of €1.00 per share for 2024, reflecting improved financial strength and resumption after legal suspension in 2023.

• Entered the "Rejuvenate" phase, focusing on innovation, operational excellence, and further financial progression.

Financial highlights

• FY 2024 revenue at €21.8 billion, up 8% organically year-over-year; EBIT before special items at €2.5 billion, up 10% in constant currency; EBIT margin at 11.6%.

• EPS grew by 14% in 2024, reversing a 13% decline in 2022; net income (excl. FMC) at €1,461 million, up 13%.

• Operating cash flow for FY 2024 at €2.4 billion, up 16%; net debt/EBITDA improved to 3.0x, lowest in seven years.

• Achieved €474 million in structural cost savings in 2024; special items included €398 million from Vamed exit.

• Return on invested capital reached 6.2%, back within the target range.

Outlook and guidance

• FY 2025 guidance: organic revenue growth of 4–6% and EBIT growth of 3–7% at constant currency.

• Kabi expected to deliver 16–16.5% EBIT margin and mid- to high-single-digit organic revenue growth; Helios to maintain around 10% EBIT margin and mid-single-digit organic revenue growth.

• Dividend policy updated to pay out 30–40% of core net income.

• Performance for 2025 expected to be second-half weighted due to phasing effects and headwinds in China and Germany.

• Upgraded financial framework: higher Kabi margin ambition (16–18%) and lower leverage target (2.5–3.0x net debt/EBITDA).